AstraZeneca and Cleveland Clinic Abu Dhabi team up for $50 million clinical trials action plan

AstraZeneca's IMFINZI with neoadjuvant EV showed significant improvements in event-free and overall survival in muscle-invasive bladder cancer patients. The combination reduced the risk of disease progression by 49% and death by 42% compared to standard care. The FDA granted Priority Review for this treatment in September 2026. The VOLGA Phase III trial involved 695 patients across 182 centers in 25 countries.

Amgen reported Phase 3 trial results showing IMDELLTRA with AstraZeneca's IMFINZI reduced death risk by 58% in extensive stage small cell lung cancer. Median progression-free survival was 7.4 months vs. 1.9 months. Safety profiles were consistent with known data. Additional data reinforced sustained outcomes. The trial included 563 patients and was sponsored by Amgen with partial funding from AstraZeneca.

AstraZeneca reported that a combination of durvalumab and Amgen's tarlatamab-dlle reduced the risk of death by 58% compared to durvalumab alone in a phase III trial for extensive-stage small cell lung cancer (ES-SCLC). The median overall survival was 21.1 months for the combination therapy versus 12.7 months for durvalumab alone.

AstraZeneca's trial showed IMFINZI plus tarlatamab-dlle improved median survival to 21.1 months vs. 12.7 months with IMFINZI alone in extensive-stage small cell lung cancer. The combination reduced death risk by 58% and progression risk by 66%. Results were consistent across subgroups, including brain metastases. AstraZeneca aims to redefine treatment standards. Data presented at ESMO Congress 2026.

Amgen's Imdelltra, combined with AstraZeneca's Imfinzi, reduced death risk by 58% in extensive-stage small cell lung cancer patients, extending median survival to 21.1 months. The trial suggests potential for Imdelltra's earlier use, boosting its commercial prospects with Q2 sales of $288M, up 115% YoY. Amgen aims to position Imdelltra as a backbone therapy for this aggressive cancer.

AstraZeneca (AZN) reported positive Phase III trial results for IMFINZI plus enfortumab vedotin in MIBC, reducing event-free survival risk by 49% and death risk by 42%. Median EFS and OS data are pending. The company aims for U.S. approval and broad use in cisplatin-ineligible patients.